Human Monoclonal Antibodies (HuMabs) are proteins created by patients' immune systems in response to specific challenges. When patients are treated with OncoVAX to prevent recurrence of their own tumors, we have the opportunity to isolate anti-cancer HuMabs with surprising properties. Using these HuMabs, we hope to create the next generation of antibody-based cancer products. Vaccinogen has lead candidates ready to evaluate for radioligand diagnostics, potential liquid biopsy assays, and bispecific antibodies (T-cell engagers), all indicated for adenocarcinomas. Adenocarcinomas are the most common types of cancer effecting the organs, and include colon, breast, kidney, lung, and many other types of cancers.
For more information or to discuss HuMabs research, please contact us at the link below.
During the development and clinical testing of OncoVAX, our vaccine for late Stage 2 and 3 colon cancer, researchers found a B-cell response to the cancer was mounted after an interim vaccination. These circulating B-cells made antibodies against the cancer neoantigens. Utilizing these cell lines, Vaccinogen was able to grow and produce HuMabs which demonstrated a unique ability to bind to antigens on an extremely wide range of cancers. By selecting one or two of these HuMabs, the researchers showed reactivity to 100% of human carcinoma.
Bispecific T-cell engagers (BiTEs) have become a leading field of interest in Oncology due to their off-the-shelf capabilities, and a number of successful examples are currently on the market. However, creating BiTEs for solid tumors has been limited by the lack of common antigens in these cancers. By leveraging the cross-reactive antigens identified by OncoVAX-treated patients, we have the opportunity to create BiTEs for a suite of andenocarcinomas, representing roughly 25% of the annual cancer burden.
By utilizing HuMabs, we hope to create a new 'liquid biopsy' which will make it possible to screen patients for cancers as easily as checking their cholesterol, at a price point significantly less than current tests.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.